Ann: Half Yearly Report and Accounts, page-11

"Sales Revenue for the period reached $2,015,499,000, a decrease of 6.1% on the prior period of $2,146,033,000. The decrease in sales revenue was heavily influenced by the reduction in demand for high cost Hepatitis C medications from March 2016. Adjusting for sales of Hepatitis C medications in the current period, Sales Revenue was down 1.4%, which was driven by a number of contributing factors including:  Volume decline during the period of 2.7%, largely caused by the loss of a customer group and generally softer consumer spend during the half  Reduced prices from the ongoing Pharmaceutical Benefits Scheme (PBS) price reform. "